SMR/ESMO Melanoma Spotlight

Long-Term Benefit Maintained Across Subgroups of Melanoma With Dabrafenib/Trametinib Combo

October 22, 2017

Adjuvant treatment with a combination of dabrafenib (Tafinlar) and trametinib (Mekinist) continues to show a long-term survival benefit in patients with melanoma, even across subgroup populations, according to a presentation at the 2017 World Congress of Melanoma (WCM).

Nivolumab/Ipilimumab Combination Shows Promise for Melanoma Brain Mets

October 21, 2017

According to updated results from the phase II ABC trial presented at the 2017 World Congress of Melanoma, Nivolumab (Opdivo) combined with ipilimumab (Yervoy) showed activity in asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.

Melanoma Research Now Focusing on Novel Combinations, Biomarkers

October 21, 2017

While immunotherapty has led a transformation for melanoma care, combinations of anti–PD-1 and CTLA-4 agents are toxic, and biomarkers are not yet available to help personalize treatment. Therefore, Carolina Robert, MD, PhD, says, further research is needed to explore less toxic, more effective options.

Pilot Study of Engineered TILs Shows Early Responses in Advanced Melanoma

October 21, 2017

In a small phase I study, engineered tumor-infiltrating lymphocytes demonstrated signs of antitumor activity in patients with metastatic melanoma following treatment with a prior checkpoint inhibitor. Results of the pilot study of TILs that were engineered to express transforming growth factor-β dominant negative receptor and nerve growth factor receptor were presented during the 2017 World Congress of Melanoma.

Immunotherapy/Targeted Therapy Combinations Show Promise in BRAF-Mutated Melanoma

October 21, 2017

Triplet therapy with the combination of anti–PD-1/PD-L1 therapy, BRAF, and MEK inhibitors have already shown promise for patients with BRAF-positive advanced melanoma, and the potential for these combinations are increasing, according to Antoni Ribas, MD, PhD.

COMBI-AD and BRIM8 Studies in Melanoma

October 21, 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

Intralesional Therapy Combinations Improve Responses Over Monotherapy in Melanoma

October 20, 2017

In patients with melanoma, the use of intralesional therapies in combination with checkpoint inhibitors has demonstrated to be an improvement to monotherapy and combinations with immunotherapy, according to a presentation by Robert Andtbacka, MD, at the 2017 World Congress of Melanoma.

Nivolumab in the Adjuvant Setting for Melanoma

October 20, 2017

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center,

Frontline Dabrafenib/Trametinib Combo Shows Promising Efficacy in BRAF+ NSCLC

September 19, 2017

Frontline treatment with the combination of dabrafenib and trametinib induced an objective response rate of 64% (95% CI, 46%-79%) and a disease control rate of 75% in patients with BRAF-mutant metastatic non–small cell lung cancer.

Majority of Melanoma Patients See Tumor Shrinkage With Dabrafenib/Trametinib Combo, But Recurrences are Common

September 18, 2017

Nearly half of patients with resectable stage IIIB/C BRAF V600-mutant melanoma achieved pathologic complete response with neoadjuvant treatment with dabrafenib and trametinib, according to results of a phase II study presented at the 2017 ESMO Congress in Madrid.